Lutetium Lu 177 Edotreotide is a targeted radiopharmaceutical therapy used in this trial. It is designed to treat tumors that have somatostatin receptors, which are often found in certain types of cancer. This therapy works by delivering radiation directly to the tumor cells, helping to destroy them while minimizing damage to surrounding healthy tissue. The trial aims to determine the appropriate dosage for children, focusing on the safety and how the body processes the therapy.

Somatostatin Receptor Positive Solid Tumors – These are a group of tumors that have receptors for the hormone somatostatin on their surface. They can occur in various parts of the body and are characterized by their ability to bind to somatostatin, which can influence their growth. These tumors may not respond to standard treatments and can recur after initial therapy. They are often monitored using imaging techniques to assess their progression. The presence of somatostatin receptors can sometimes be used to target specific therapies. These tumors are considered rare, especially in pediatric patients.

Lymphoma – Lymphoma is a type of cancer that begins in the lymphatic system, which is part of the body’s immune system. It involves the abnormal growth of lymphocytes, a type of white blood cell, which can form tumors in lymph nodes and other parts of the body. Lymphoma can be classified into Hodgkin and non-Hodgkin types, each with different characteristics and progression patterns. It can cause symptoms such as swollen lymph nodes, fever, and weight loss. The disease can be recurrent or refractory, meaning it may return after treatment or not respond to standard therapies. Monitoring and imaging are crucial for assessing the disease’s progression and response to treatment.